Form 10-K Fulcrum Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
Stifel on Fulcrum Therapeutics (FULC): 'we think overly nitpicking 19.3% is splitting hairs and misses the bigger picture'
February 24, 2026 10:23 AM ESTStifel analyst Dae Gon Ha reiterated a Buy rating and $25.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).
The analyst comments "The move this morning surprises us. While we think some thought total mean HbF may comfortably be >20% given the strength of the... More
